Natera, Inc. (NASDAQ:NTRA) Stock Has Average Target Price of $394.31 According to Brokerages

Shares of Natera, Inc. (NASDAQ:NTRA) have received an average rating of “Moderate Buy” from the twenty-three analysts that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, seventeen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $391.69.

Several brokerages have recently weighed in on NTRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Roth Capital assumed coverage on Natera in a research note on Thursday, October 22nd. They issued a “buy” rating and a $475.00 price target on the stock. Leerink Partners set a $330.00 price objective on Natera in a research report on Friday, August 7th. Piper Sandler restated an “overweight” rating and set a $363.50 price objective on shares of Natera in a research note on Friday. Finally, Guggenheim boosted their target price on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st.

Natera Price Performance

Natera stock opened at $310.67 on Wednesday. Natera has a 12-month low of $181.00 and a 12-month high of $437.41. The firm has a 50 day moving average of $380.25 and a 200 day moving average of $269.68.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The company had revenue of $793.98 million for the quarter, compared to analyst estimates of $707.54 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company’s quarterly revenue was up 34.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. Sell-side analysts predict that Natera will post -1.14 earnings per share for the current year.

Insider Activity

In other news, CFO Michael Brophy sold 1,906 shares of the company’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $425.55, for a total value of $811,098.30. Following the transaction, the chief financial officer owned 46,574 shares of the company’s stock, valued at $19,819,565.70. This represents a 3.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Fesko sold 6,517 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the sale, the insider owned 197,257 shares in the company, valued at approximately $63,424,043.21. This trade represents a 3.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 53,573 shares of company stock worth $19,856,400 in the last quarter. Corporate insiders own 5.05% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co boosted its holdings in Natera by 81.4% in the third quarter. Diversified Trust Co now owns 2,353 shares of the medical research company’s stock valued at $973,000 after acquiring an additional 1,056 shares during the last quarter. Aberdeen Group plc grew its holdings in Natera by 26,462.7% during the third quarter. Aberdeen Group plc now owns 1,398,794 shares of the medical research company’s stock worth $578,136,000 after acquiring an additional 1,393,528 shares during the period. HBE Wealth Management LLC purchased a new stake in shares of Natera in the 3rd quarter valued at approximately $208,000. Allworth Financial LP lifted its holdings in Natera by 2.5% during the 3rd quarter. Allworth Financial LP now owns 3,975 shares of the medical research company’s stock worth $1,643,000 after buying an additional 97 shares during the last quarter. Finally, Private Advisory Group LLC purchased a new stake in Natera during the third quarter worth about $3,521,000. Institutional investors own 99.90% of the company’s stock.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
• Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
• Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Natera Company Profile

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.